BIOHARVEST SCIENCES INC. UNVEILS NEW GROUNDBREAKING CANNABIS TRICHOME STRUCTURE

 

  • New innovative “Amalgamated Trichomes Coral Structure” withstands shear forces applied by the liquid medium
  • New structure acts as a protective shield enabling stable trichome development throughout the growth process
  • Historic scientific milestone validates BioHarvest’s path to commercialization of Cannabis in H1 2022

VANCOUVER, CANADA, and REHOVOT, ISRAEL, August 19th, 2021 – BioHarvest Sciences Inc.’s (“BioHarvest” or the “Company”) (CSE: BHSC) today unveiled a new, groundbreaking “Amalgamated Trichomes Coral Structure” (ATCS) that will revolutionize the production of Cannabis.  BioHarvest has successfully grown multiple trichomes in coral-shaped clusters where they are attached together in a natural structure. This structure protects the trichomes from the shear forces and guarantees much-needed mechanical stability during the growth process.

 The trichomes (the natural cannabinoids micro-factories of the Cannabis plant – picture 3) grow on the surface of the Cannabis flower or leaf and have a shape of a tiny mushroom with glandular heads. They are individually and mechanically attached to the surface through a fragile stalk. BioHarvest is the first company in the world to successfully and naturally grow trichomes together, forming a coral-shaped structure (pictures 1 and 2) that protects them from the shear forces applied by the fluid motion inside the bioreactors. This structure guarantees the much-needed mechanical stability during the growth process within the bioreactor. We call this uniquely shaped structure “Amalgamated Trichomes Coral Structure” (ATCS), and it allows the Company to quickly scale up Cannabis production in advance of wide-scale commercialization in H1 2022.

Dr. Yochi Hagay, CTO of BioHarvest, said: “ATCS is instrumental in the ability to grow trichomes cells in bioreactors at scale. Over the last decade, BioHarvest’s world-class R&D team demonstrated unparalleled expertise in plant cell biology. This achievement is particularly notable given the complexity of Cannabis, and I have no doubt in this team’s ability to apply it on any plant in the future.

Ilan Sobel, CEO of BioHarvest, said: “ATCS brings us one step closer to the completion of the Cannabis development program. The patented BioFarming technology, along with such in-house expertise, is creating tremendous biotech market opportunities for BioHarvest. I look forward to showing the world in H1/2022 the Company’s Cannabis-based products and to unveiling new conquered frontiers by our BioFarming technology.

Eitan Popper, Chairman of BioHarvest’s Board of Advisors, and Co-Founder and former President of MedReleaf, stated: “One of the main questions I raised when I first met BioHarvest’s management, was whether the Company’s technology would allow for Cannabis trichomes to stably grow in liquid media. Even intuitively, this is far from trivial, as Cannabis trichome cells grown in liquid media lack the static mechanical support they have when growing on top of or attached to the solid Cannabis flower or leaf tissue. The challenge is two-fold, not only liquid media vs. solid plant tissue but also dynamic flow conditions vs. static conditions. Put simply, how do you stably proliferate and guarantee the physical integrity of fragile plant organs grown in a liquid that is circulating or flowing within a bioreactor. BioHarvest has solved this with proprietary IP that is specific to Cannabis. It is fascinating from a scientific point of view and very encouraging from a business potential perspective for Cannabis and beyond.

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.’s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Media Contact

Will Hummel

+31639177280

William.Hummel@BOLDTpartners.com

 

Forward-Looking Statements 

Information set forth in this news release includes might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance the Company will be able to successfully convert the exiting 2 tons/year VINIA® facility to a Cannabis production facility in H1, 2022 and there is no guarantee that the new facility will begin production of VINIA® end of September 2021. There is no assurance we will be able to commercialize our first Cannabis products in the first half of 2022 and there is no assurance the Company will be able to add new verticals or build additional plants elsewhere. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. The success of the Company in demonstrating its ability to consistently grow in solution trichomes from multiple plant strains is not an assurance that the Company will be able to commence commercial production when anticipated or at all. While the Company is in the process of constructing a two-ton production facility the Company’s current licensing only permits scientific research. Projected sales of Cannabis will require the Company to obtain production and or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.